Inactive Instrument

KemPharm, Inc. Stock price Other OTC

Equities

Pharmaceuticals

Sales 2023 * 25.98M Sales 2024 * 34.54M Capitalization 246M
Net income 2023 * -43M Net income 2024 * -51M EV / Sales 2023 * 8.07 x
Net cash position 2023 * 36.8M Net Debt 2024 * 3.3M EV / Sales 2024 * 7.23 x
P/E ratio 2023 *
-5.02 x
P/E ratio 2024 *
-4.68 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 88.61%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder 44 06-10-29
Chief Executive Officer 52 23-10-09
Director of Finance/CFO 51 15-03-31
Members of the board TitleAgeSince
Director/Board Member 68 23-04-24
Director/Board Member 60 15-03-09
Chairman 65 21-08-17
More insiders
Zevra Therapeutics, Inc. is a rare disease company melding science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA. Its pipeline also includes EDSIVO and others.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Zevra Therapeutics, Inc.
  4. Stock KemPharm, Inc. - Other OTC